Abstract:Multimodal imaging for precision medicine has received significant attention in recent years. In this work, we proposed to combine Cerenkov luminescence imaging (CLI) and SPECT-CT to systematically evaluate the real biodistribution of nanoscale metal-organic framework (MOF) in murine xenograft model. 177 Lu was incorporated into nanoscale MOF-76(Eu)/FA in high radiochemical yield to construct a multimodal probe with physiological stability. Subsequently, the 177 Lu-MOF-76(Eu)/FA shows adequate in vitro affinity and cytotoxicity to cancer cells. Furthermore, by comparing the SPECT imaging and CLI, we evaluated the feasibility of in vivo CLI application in preclinical studies of 177 Lu-radiopharmaceuticals. The results demonstrate that CLI address some limitations of fluorescence imaging based on organic dye molecule and enable accurate tracking 177 Lu radiolabeled compounds in major organs.

In vivo evaluation of Cerenkov luminescence and SPECT imaging for nanoscale 177 Lu-labeled metal-organic framework